Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
NCT01508949 on ClinicalTrials.gov · last registry update 2023-11-02
A small phase 2 — 35 participants, against a typical 110. The sponsor logged completion for March 2002. Primary outcome, as filed: Change in weight. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 35
- Started
- 2001-06
- Primary completion
- 2002-03 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in weight
Conditions studied
Diabetes · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.